Traditional cancer diagnostics often rely heavily on tissue biopsies—a process that is invasive, painful, and suffering from sampling limitations that may miss tumor heterogeneity. Enter exRNA, accessible via liquid biopsies—non-invasive tests performed on body fluids such as blood or urine. Unlike conventional methods, exRNA profiling permits continuous monitoring of tumor dynamics in real-time, providing critical insights into mutation status, drug resistance development, and metastatic potential. These RNA molecules remain remarkably stable in circulation due to their enclosure within extracellular vesicles and bind to protein complexes, making them robust candidates for clinical diagnostics.

The molecular composition of exRNA is strikingly diverse. Among the most studied are microRNAs (miRNAs) and circular RNAs (circRNAs), which have demonstrated a sensitive ability to differentiate between healthy and cancerous states across various tumor types, including but not limited to lung, pancreatic, colorectal, and prostate cancers. These small RNAs act as molecular fingerprints emitted by cancerous cells; deciphering their signatures allows oncologists to pinpoint tumor type, aggressiveness, and even predict therapeutic responsiveness with increased accuracy.

Beyond diagnostics, the therapeutic potential of exRNA-loaded exosomes is swiftly progressing from speculative to demonstrable. Bioengineers are now designing exosome-mimetic nanocarriers to deliver therapeutic RNA species capable of silencing oncogenes or reinstating tumor suppressor pathways within cancer cells. This targeted delivery system minimizes off-target effects seen with systemic chemotherapies and offers the tantalizing possibility of reversing established drug resistance. Preclinical models already illustrate compelling results, with RNA-loaded exosomes significantly suppressing tumor growth and enhancing the efficacy of existing drugs.

However, the journey from laboratory innovation to clinical application is fraught with challenges. One major bottleneck is the lack of standardized protocols for isolating and characterizing exRNAs and their vesicular carriers. Variability in sample collection, purification methods, and analytical techniques hampers reproducibility and cross-study comparisons. Moreover, manufacturing exosome-based therapeutics at scale under stringent regulatory standards remains unresolved, with concerns about batch consistency, purity, and potential immunogenicity.

Intricately linked to these challenges are the complexities of in vivo targeting. Ensuring that therapeutic exosomes reach their intended cancer cell populations without rapid clearance or unintended organ accumulation is a significant technical hurdle. Advances in molecular engineering, such as modifying exosomal surface proteins to enhance tissue tropism, are actively under investigation but require extensive validation. Parallel developments in artificial intelligence (AI) promise to accelerate these processes by enabling sophisticated pattern recognition and predictive modeling of exRNA profiles and treatment outcomes.

The implications of integrating AI with exRNA-based technologies extend far beyond mere diagnostics. AI algorithms can assimilate multifaceted molecular data sets to refine patient stratification, optimize individualized therapy regimens, and monitor treatment response with unprecedented precision. This convergence of molecular biology and computational power heralds a new era of precision oncology, where treatments are dynamically tailored not only to tumor genomics but to its evolving molecular environment.

This multidisciplinary synergy is reflected by the collaborative efforts of molecular biologists, bioengineers, clinicians, and data scientists driving this field forward. Their combined expertise is essential to unravel the complexity of exRNA biology—ranging from mechanisms of RNA sorting into exosomes to decoding intercellular communication pathways manipulated by tumors. Understanding these nuances is critical for harnessing exRNAs both as messengers dictating cancer progression and as vehicles delivering molecular interventions.

Importantly, as this research continues, ethical and regulatory considerations must keep pace. Robust clinical trials evaluating the safety and efficacy of exRNA therapeutics are imperative, along with frameworks to govern their clinical use and patient consent. Meanwhile, public and private investment in infrastructure and talent development will accelerate translation from bench to bedside, ensuring that these technologies do not remain confined to theoretical possibilities.

The reviewed literature posits a future where a simple blood test can simultaneously detect cancer presence, characterize its molecular profile, and administer targeted RNA therapies—all within a unified clinical workflow. This would signify a monumental leap in cancer care, mitigating the physical and psychological burdens patients currently endure and tailoring interventions with extraordinary specificity. While significant work remains, the horizon gleams bright with the promise of exRNA-based theranostics reshaping oncological landscapes.

Researchers emphasize that continued interdisciplinary collaboration and technological innovation will be catalysts in overcoming present-day barriers. By deepening our grasp of exRNA biology and enhancing bioengineering capabilities, exRNA-centered diagnostics and therapeutics may soon become integral components of routine cancer management. Such progress aligns with the overarching aspirations of precision medicine: to improve outcomes while minimizing harm.

This review is not merely a catalog of current achievements but a clarion call to the scientific community to recognize and unlock the vast potential of exRNAs. It underscores that the integration of molecular biology, nanotechnology, and artificial intelligence represents a transformative frontier in oncology. With concerted efforts, the vision of exRNA-guided, personalized cancer treatment is poised to transition from the realm of promise to that of clinical reality.

Subject of Research: Not applicable

Article Title: ExRNA as theranostic agents in cancer: current progress and future perspectives

News Publication Date: 25-Jul-2025

Web References: 10.55092/exrna20250008

References: Nik Abd Rahman, N.M.A., et al., ExRNA as theranostic agents in cancer: current progress and future perspectives. ExRNA, 2025. 7(2).

Image Credits: Nik Mohd Afizan Nik Abd Rahman, Che Nur Mazadillina Che Zahari, Mohd Azuraidi Osman, Noorjahan Banu Mohamed Alitheen/Universiti Putra Malaysia, Nur Akmarina Mohd Said/Universiti Malaya, Shazreen Shaharuddin/Universiti Pertahanan Nasional Malaysia, Putri Cahaya Situmorang/Universitas Sumatera Utara

Keywords: Cancer

Nasopharyngeal carcinoma, a malignancy arising from the epithelial lining of the nasopharynx, presents a clinical challenge due to its often asymptomatic early stages and complex anatomical location. Conventional diagnostic methods, while effective in some contexts, have struggled with sensitivity and specificity, often necessitating invasive biopsies or reliance on plasma-based EBV markers that can be limited by fluctuating viral loads and tumor heterogeneity. Addressing these challenges, the current study delves into the epigenetic landscape of NPC by analyzing methylation status of three critical genes: SEPTIN9, RASSF1A, and H4C6.

DNA methylation, an early and stable epigenetic modification, plays a pivotal role in gene expression regulation and carcinogenesis. Aberrant methylation patterns frequently accompany malignant transformation, making methylated genes attractive candidates for diagnostic biomarker development. The investigative team collected a total of 255 nasopharyngeal swabs alongside 35 plasma samples from patients diagnosed with either newly identified or treated NPC, coupled with healthy control samples, to comprehensively assess the diagnostic potential of these methylation markers.

Employing methylation-specific polymerase chain reaction (MSP), the researchers meticulously quantified the methylation levels of SEPTIN9, RASSF1A, and H4C6, genes previously implicated in various cancer types. By focusing on nasopharyngeal swabs rather than solely plasma, this study pioneers a more direct sampling of the tumor microenvironment, potentially capturing methylation signatures with greater fidelity to localized disease processes.

The results are striking. The detection rates of methylated SEPTIN9, RASSF1A, and H4C6 in nasopharyngeal swabs from newly diagnosed NPC patients were 88.2%, 92.9%, and 71.8%, respectively. This contrasts markedly with detection from plasma samples, which yielded significantly lower rates—54.3%, 42.9%, and 45.7%, respectively. These findings underscore the enhanced sensitivity attainable through targeted swab sampling directly from the nasopharyngeal cavity.

In distinguishing NPC patients from healthy controls, methylated RASSF1A emerged as the most potent diagnostic marker, achieving a sensitivity of 93% and an impressive area under the receiver operating characteristic curve (AUC) of 0.956. Such high classification accuracy signifies that RASSF1A methylation analysis could serve as a reliable standalone screening modality or in conjunction with other markers for refined diagnostic precision.

The methodological innovation of automated bilateral nasal swab processing is particularly noteworthy, offering a rapid, standardized, and patient-friendly approach that circumvents the discomfort and logistical difficulties of biopsy or more invasive procedures. This automation could facilitate widespread clinical implementation, enhancing screening accessibility and adherence, especially in resource-limited settings or populations at elevated risk of NPC.

Furthermore, the study provides an important comparison between paired swab and plasma samples, demonstrating that nasopharyngeal swabs considerably outperform plasma in detecting methylated nucleic acids reflective of tumor presence. This differential could be attributed to the higher concentration of tumor DNA in mucosal surfaces adjacent to the neoplasm versus the diluted and variably circulating tumor DNA in plasma.

These findings are not merely academic; they carry profound implications for public health. Early detection of NPC dramatically improves prognosis, given that treatment is more effective at localized stages before metastasis occurs. By harnessing an epigenetic biomarker panel from minimally invasive sampling, clinicians may soon be equipped to identify NPC at an earlier phase, potentially reducing mortality rates in high-incidence regions.

The inclusion of SEPTIN9 and H4C6 alongside RASSF1A enhances the robustness of the biomarker panel, although RASSF1A maintains predominance in diagnostic strength. This triad of genes represents a novel multi-gene methylation signature, enriching the toolkit available for molecular epidemiology and precision oncology in head and neck cancers.

It is also essential to contextualize this advancement within the broader landscape of NPC diagnostics. Epstein-Barr virus (EBV) viral load measurements, while valuable, suffer from inconsistencies and sensitivity limitations. The incorporation of DNA methylation markers offers a complementary or alternative axis of detection that is rooted in tumor-specific epigenetic changes rather than viral presence alone.

Practically, the study’s success in real-world clinical sampling conditions bolsters its translational viability. The automatically processed bilateral nasal swab technique was successfully applied in a clinical setting, reflecting potential scalability and minimal disruption to existing care workflows.

As the demand for non-invasive cancer diagnostics accelerates, this study exemplifies how integrating molecular epigenetics with innovative sample acquisition can pave new paths in oncology. Its approach could inspire similar methylation-based assays for other cancers accessible by swabbing, expanding the frontier of liquid biopsy beyond blood.

Nevertheless, challenges remain. Future investigations must validate these findings in larger, diverse cohorts and ascertain longitudinal biomarker dynamics to determine their utility in monitoring disease progression and recurrence. Moreover, optimizing assay sensitivity and cost-effectiveness will be key to ensuring broad accessibility.

In conclusion, the detection of RASSF1A methylation from bilateral nasal swabs represents a significant leap forward in NPC diagnostics. This non-invasive, accurate, and patient-friendly methodology holds promise not only for earlier detection but also for enhancing clinical decision-making and personalized patient management in nasopharyngeal carcinoma.

Subject of Research: Nasopharyngeal carcinoma detection through epigenetic methylation analysis in nasal swab samples.

Article Title: Nasopharyngeal carcinoma detected noninvasively in the real world using three gene methylation analyses from automatically processed bilateral nasal swab samples

Article References:
Qin, ZH., Chen, SY., Zhou, S. et al. Nasopharyngeal carcinoma detected noninvasively in the real world using three gene methylation analyses from automatically processed bilateral nasal swab samples. BMC Cancer 25, 1147 (2025). https://doi.org/10.1186/s12885-025-14508-y

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14508-y